Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

30.25USD
23 Apr 2018
Change (% chg)

$-0.55 (-1.79%)
Prev Close
$30.80
Open
$30.49
Day's High
$30.77
Day's Low
$29.30
Volume
156,340
Avg. Vol
193,829
52-wk High
$41.24
52-wk Low
$22.68

Latest Key Developments (Source: Significant Developments)

La Jolla PharmaAnnounces Launch Of Giapreza In United States
Thursday, 22 Mar 2018 04:01pm EDT 

March 22 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES.LA JOLLA PHARMACEUTICAL CO - GIAPREZA IS AVAILABLE IN 1 ML SINGLE-DOSE VIALS, EACH CONTAINING 2.5 MG OF ANGIOTENSIN II.  Full Article

La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE.SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE.  Full Article

La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock
Wednesday, 14 Mar 2018 04:01pm EDT 

March 14 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK.  Full Article

La Jolla Pharmaceutical Q4 Loss Per Share $1.74
Thursday, 22 Feb 2018 05:16pm EST 

Feb 22 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS.Q4 LOSS PER SHARE $1.74.  Full Article

Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​
Thursday, 11 Jan 2018 05:12pm EST 

Jan 11 (Reuters) - La Jolla Pharmaceutical Co ::BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​.  Full Article

La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018
Friday, 29 Dec 2017 04:40pm EST 

Dec 29 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING.  Full Article

La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure
Thursday, 21 Dec 2017 06:17pm EST 

Dec 21 (Reuters) - La Jolla Pharmaceutical Co ::U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE.U.S. FDA SAYS GRANTED THE APPROVAL OF GIAPREZA TO LA JOLLA PHARMACEUTICAL COMPANY.U.S. FDA - APPROVES GIAPREZA (ANGIOTENSIN II) INJECTION FOR INTRAVENOUS INFUSION TO INCREASE BLOOD PRESSURE IN ADULTS WITH SEPTIC/OTHER DISTRIBUTIVE SHOCK.  Full Article

La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401
Monday, 18 Dec 2017 09:00am EST 

Dec 18 (Reuters) - La Jolla Pharmaceutical Co ::INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC‑401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS.  Full Article

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 05:42pm EDT 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

La Jolla reports Q3 loss $1.19/shr
Thursday, 26 Oct 2017 05:10pm EDT 

Oct 26 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Q3 loss per share $1.19.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.La Jolla Pharmaceutical-‍as of Sept 30, 2017, co had $120.8 million in cash,cash equivalents, versus $65.7 million of cash and cash equivalents at Dec 31, 2016​.  Full Article

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES